BR Biopharma (NASDAQ:BRBI) Issues Quarterly Earnings Results

BR Biopharma (NASDAQ:BRBIGet Free Report) posted its earnings results on Thursday. The company reported $0.09 EPS for the quarter, FiscalAI reports. The company had revenue of $25.13 million during the quarter.

BR Biopharma Price Performance

Shares of BRBI stock traded down $0.24 during mid-day trading on Thursday, reaching $11.21. 302 shares of the company’s stock traded hands, compared to its average volume of 165. BR Biopharma has a 12 month low of $10.90 and a 12 month high of $67.01. The firm’s 50 day moving average price is $11.66.

BR Biopharma Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, June 5th. Stockholders of record on Tuesday, May 19th were paid a dividend of $0.147 per share. This represents a $0.59 annualized dividend and a dividend yield of 5.2%. The ex-dividend date was Tuesday, May 19th.

Analysts Set New Price Targets

Separately, Weiss Ratings raised BR Biopharma from a “sell (e)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

Read Our Latest Research Report on BR Biopharma

Hedge Funds Weigh In On BR Biopharma

An institutional investor recently bought a new position in BR Biopharma stock. Acuitas Investments LLC bought a new stake in shares of BR Biopharma, Inc. (NASDAQ:BRBIFree Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 3,000 shares of the company’s stock, valued at approximately $45,000. BR Biopharma makes up approximately 3.2% of Acuitas Investments LLC’s holdings, making the stock its 7th biggest position.

BR Biopharma Company Profile

(Get Free Report)

BRBI BR Partners SA, through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners SA is based in S?o Paulo, Brazil.

Recommended Stories

Receive News & Ratings for BR Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BR Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.